newsfilter
← Latest News
GlobeNewswire·

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...